Truist Financial Boosts Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) had its target price increased by Truist Financial from $341.00 to $456.00 in a research note issued to investors on Tuesday morning, The Fly reports. VRTX has been the topic of several other reports. Robert W. Baird lifted their price target on shares of Vertex Pharmaceuticals from $280.00 to […]

Related Keywords

Sanfordc Bernstein , Robertw Baird , David Altshuler , Stuarta Arbuckle , Wealth Advisors Inc , Parkside Financial Bank , Insider Activity At Vertex Pharmaceuticals , Securities Exchange Commission , Vertex Pharmaceuticals Company Profile , Institutional Trading Of Vertex Pharmaceuticals , Analyst Recommendations For Vertex Pharmaceuticals , Bergankdv Wealth Management , Vertex Pharmaceuticals , News Ratings For Vertex Pharmaceuticals Daily , Farmers Merchants Investments Inc , Vertex Pharmaceuticals Inc , Vertex Pharmaceuticals Stock Performance , Get Rating , Truist Financial , Moderate Buy , Exchange Commission , Merchants Investments , Financial Bank , Vertex Pharmaceuticals Daily , Nasdaq Vrtx , Vrtx , Medical , 92532f10 , Boost Price Target , Truist Financial Co ,